Full course description
Comprehensive Contraceptive Education:
Colorado Senate Bill 16-135 created the infrastructure for the Colorado Boards of Pharmacy, Medicine, and Nursing to work collaboratively with the Colorado Department of Public Health and Environment to create statewide protocols to address public health needs. The first such statewide protocol is self-administered contraception. In 2022, the protocol was further expanded to include depot medroxyprogesterone acetate (Depo-Provera®) and the vaginal ring products.
The University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences is honored to partner with Oregon State University to offer this training program that allows Colorado pharmacists to meet the requirements necessary to provide contraceptive care to women in our state. We are now the third state in the nation to allow pharmacists to prescribe contraceptives. The Colorado statute provides this per protocol.
Women in the United States have had access to highly effective hormonal contraception in the form of an oral pill for decades. However, they have always needed to see their doctor or women’s health provider in order to get a prescription for it, causing what many believe to be an unnecessary hurdle. The American Congress of Obstetricians and Gynecologists (ACOG) have issued a formal statement that self-administered hormonal contraception should be made more accessible by removing this barrier. This is because the benefit of preventing unintended pregnancies by improving access to hormonal contraception outweighs the small risks associated with serious adverse events.
While pharmacists are knowledgeable in being able to counsel women on the side effects and what to expect, before now they have never been in the role of starting or continuing a woman on any form of hormonal contraception. It is good to have a foundational knowledge on hormonal contraception, but prescribing it requires a deeper understanding of how to practice seeing patients and in making clinical decisions.
This training program has received significant support and guidance from several OBGYN members of ACOG, and is specifically designed to give pharmacists the tools needed to be confident and successful in prescribing and monitoring self-administered hormonal contraception.
Accreditation Council for Pharmacy Education Information:
This program has been planned and implemented in accordance with the policies of the Accreditation Council for Pharmacy Education through the sponsorship of OSU College of Pharmacy. The OSU College of Pharmacy is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Upon completion of this activity, participants will receive a Statement of Completion, and a Statement of Credit shall be uploaded to CPE Monitor. Completion requires 1) Registration for the course 2) Completion of all modules 3) Passing a final exam with 80% or higher and 4) Completion of the program evaluation.
At the completion of this activity, the participant will be able to:
1) Work with an individual woman to choose the best and most effective contraceptive method for her.
2) Build a strong knowledge base for hormonal contraceptives including the mechanism of action, doses, types, use, benefits, and risks.
3) Effectively counsel patients on the importance of adherence, missed pills, interactions, and side effects of combined hormonal contraceptives.
4) Recognize the purpose of the self-assessment questionnaire, and how it relates to the US Medical Eligible Criteria guidelines published by the CDC.
5) Assess an individual woman's risk when compared to the benefits of combined hormonal contraceptions in order to determine whether or not she should be referred to her women's health provider.
6) Utilize tools that will aid in how to incorporate a service that provides hormonal contraception to women at a community pharmacy or ambulatory care site.
7) Compare DMPA to other "self-administered" hormonal contraceptive methods including the oral pill, the transdermal patch, and the vaginal ring.
8) Evaluate the risks associated with DMPA, and other progestin-only methods, for a given patient in order to determine her eligibility for use.
Activity Type: Application
Activity Release Date: 01/01/2022
Activity Expiration Date: 01/01/2025
Contributors: Lorinda Anderson, PharmD, BCPS; Mark Leid, PhD, BPharm; Adriane Irwin, MS, PharmD, BCACP
Disclosures: None of the contributors, designers, or peer reviewers for this course have any financial relationships with ineligible companies to disclose
The following browsers are supported for enrollment and completion of this course. If you are completing the course on a phone or tablet, it is recommended to utlize the Canvas app available in the Apple or Google app store.
- Chrome 102 and 103
- Firefox 100 and 101 (*extended releases are not supported)
- Edge 101 and 102
- Respondus Lockdown Browser (supporting the latest system requirements)
- Safari 14 and 15 (Macintosh only)
About the Course:
The guidelines for contraceptive use put out by the CDC have an app that can be downloaded for use. You can find it by searching "US MEC US SPR" in iTunes or Google Play, or by clicking on this link and scrolling down: US MEC App, the guidelines for contraceptive use put out by the CDC.
An NABP e-Profile ID and NPI number must be provided to complete the registration process, if you need help credentialing please contact the OSU College of Pharmacy.
If you have any questions regarding the course, please contact OSU College of Pharmacy.
If you've already completed one of our ACPE accredited state courses and need certification in an additional state(s), please click here to complete the form request.